Shattuck Labs Inc
STTK1.930USD
-0.060-3.02%
收盘 11/04, 16:00（美东）报价延迟15分钟
92.45M总市值
亏损市盈率 TTM
关于 Shattuck Labs Inc 公司
Shattuck Labs, Inc. 是一家临床阶段的生物技术公司。该公司致力于开发双功能融合蛋白，作为治疗癌症和自身免疫性疾病患者的一类新型生物药物。其主要候选产品 SL-172154 旨在同时抑制 CD47/SIRPa 巨噬细胞检查点相互作用并激活 CD40 共刺激受体以诱导抗肿瘤免疫反应。该公司正在对急性髓系白血病 (AML) 和 HR-MDS 患者进行 IA/B 期临床试验。该公司已完成该临床试验的 IA 期剂量递增部分，并正在招募 IB 期扩展队列中的患者，评估 SL-172154 与阿扎胞苷联合用于一线 HR-MDS 或一线 TP53 突变 (TP53m) AML 的疗效。该公司开发了 ARC 平台，以满足对单一疗法整合多种免疫功能的需求。
Shattuck Labs Inc简介
公司代码STTK
公司名称Shattuck Labs Inc
上市日期Oct 09, 2020
CEODr. Taylor Schreiber, M.D., Ph.D.
员工数量44
证券类型Ordinary Share
年结日Oct 09
公司地址500 W. 5Th Street
城市AUSTIN
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编78701
电话15129004690
网址https://www.shattucklabs.com/
公司代码STTK
上市日期Oct 09, 2020
CEODr. Taylor Schreiber, M.D., Ph.D.
Shattuck Labs Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
96.61K
+36.07%
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
86.28K
+17.43%
Ms. Casi Deyoung
Ms. Casi Deyoung
Chief Business Officer
Chief Business Officer
81.47K
-8.97%
Dr. George S. Golumbeski, Ph.D.
Dr. George S. Golumbeski, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.61K
--
Dr. Neil W. Gibson ,Ph.D.
Dr. Neil W. Gibson ,Ph.D.
Independent Director
Independent Director
52.74K
--
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Mr. Conor Richardson, CPA
Mr. Conor Richardson, CPA
Senior Director, Finance & Investor Relations
Senior Director, Finance & Investor Relations
--
--
Dr. Clay Siegall, Ph.D.
Dr. Clay Siegall, Ph.D.
Independent Director
Independent Director
--
--
Mr. Andrew R. Neill
Mr. Andrew R. Neill
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Abhinav A. Shukla, Ph.D.
Dr. Abhinav A. Shukla, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
96.61K
+36.07%
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
86.28K
+17.43%
Ms. Casi Deyoung
Ms. Casi Deyoung
Chief Business Officer
Chief Business Officer
81.47K
-8.97%
Dr. George S. Golumbeski, Ph.D.
Dr. George S. Golumbeski, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.61K
--
Dr. Neil W. Gibson ,Ph.D.
Dr. Neil W. Gibson ,Ph.D.
Independent Director
Independent Director
52.74K
--
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 9月6日 周六
更新时间: 9月6日 周六
持股股东
股东类型
持股股东
持股股东
占比
Prosight Capital
13.86%
OrbiMed Advisors, LLC
13.16%
Redmile Group, LLC
11.56%
Adage Capital Management, L.P.
9.76%
Hornblower Capital Holdings, LLC
6.04%
其他
45.62%
持股股东
持股股东
占比
Prosight Capital
13.86%
OrbiMed Advisors, LLC
13.16%
Redmile Group, LLC
11.56%
Adage Capital Management, L.P.
9.76%
Hornblower Capital Holdings, LLC
6.04%
其他
45.62%
股东类型
持股股东
占比
Hedge Fund
28.47%
Investment Advisor/Hedge Fund
17.06%
Private Equity
13.16%
Corporation
12.56%
Investment Advisor
8.13%
Family Office
3.74%
Individual Investor
2.44%
Research Firm
1.52%
其他
12.91%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
179
32.74M
68.35%
-1.53M
2025Q2
186
35.33M
73.76%
-6.35M
2025Q1
190
36.10M
75.45%
-5.76M
2024Q4
182
37.00M
77.49%
-7.77M
2024Q3
191
41.87M
87.75%
-1.86M
2024Q2
194
39.66M
83.35%
+16.66K
2024Q1
209
37.10M
79.60%
-1.39M
2023Q4
203
34.54M
71.04%
+5.75M
2023Q3
205
27.35M
64.28%
-7.93M
2023Q2
215
27.61M
64.91%
-8.42M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Prosight Capital
6.64M
13.86%
--
--
Jun 30, 2025
OrbiMed Advisors, LLC
6.31M
13.16%
+6.31M
--
Sep 02, 2025
Redmile Group, LLC
5.54M
11.56%
--
--
Aug 25, 2025
Adage Capital Management, L.P.
4.67M
9.76%
--
--
Jun 30, 2025
Hornblower Capital Holdings, LLC
2.89M
6.04%
--
--
Apr 01, 2025
Houghton Capital Holdings, LLC
2.61M
5.45%
--
--
Apr 01, 2025
The Vanguard Group, Inc.
2.15M
4.48%
-252.36K
-10.51%
Jun 30, 2025
The Clark Estates Inc.
1.48M
3.08%
--
--
Jun 30, 2025
Pinnacle Associates Ltd.
1.36M
2.85%
+64.00K
+4.92%
Jun 30, 2025
683 Capital Management LLC
1.09M
2.29%
+45.00K
+4.29%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月2日 周日
更新时间: 11月2日 周日
机构名称
占比
Texas Capital Texas Equity Index ETF
0%
iShares Russell 2000 Value ETF
0%
ProShares UltraPro Russell2000
0%
Dimensional US Core Equity 1 ETF
0%
ProShares Hedge Replication ETF
0%
iShares Morningstar Small-Cap ETF
0%
iShares Russell 2000 ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
Texas Capital Texas Small Cap Equity Index ETF
0%
查看更多
Texas Capital Texas Equity Index ETF
占比0%
iShares Russell 2000 Value ETF
占比0%
ProShares UltraPro Russell2000
占比0%
Dimensional US Core Equity 1 ETF
占比0%
ProShares Hedge Replication ETF
占比0%
iShares Morningstar Small-Cap ETF
占比0%
iShares Russell 2000 ETF
占比0%
Avantis US Small Cap Equity ETF
占比0%
iShares Micro-Cap ETF
占比0%
Texas Capital Texas Small Cap Equity Index ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
